Trade Gilead ^GILD

Promising Pharmaceutical Stocks To Watch Now - May 9th - Stock Observer

Gilead Sciences (NASDAQ:GILD) Price Target Lowered to $146.00 at Leerink Partners - Zolmax

Leerink Partners Lowers Gilead Sciences (NASDAQ:GILD) Price Target to $146.00 - Stock Observer

Crossmark Global Holdings Inc. Buys 23,719 Shares of Gilead Sciences, Inc. $GILD

Gilead Sciences (NASDAQ:GILD) Price Target Cut to $146.00 by Analysts at Leerink Partners - Daily Political

Morgan Stanley Issues Pessimistic Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - Daily Political

Gilead Sciences (NASDAQ:GILD) Stock Rating Lowered by Wall Street Zen

Gilead Sciences (GILD) Margin Surge Tests Cautious Growth Narratives After FY 2025 Results

RBC Capital Reaffirms Their Hold Rating on Aardvark Therapeutics, Inc. (AARD)

Prothena (PRTA) Gets a Hold from RBC Capital

Gilead Earnings: Strong HIV Growth Counters CAR-T Weakness, but Anito-Cel Launch in Focus | Morningstar

GILD Maintained by RBC Capital -- Price Target Lowered to $122

Gilead Sciences (NASDAQ:GILD) Price Target Cut to $122.00 by Analysts at Royal Bank Of Canada

Gilead Sciences, Inc. (NASDAQ:GILD) Plans Quarterly Dividend of $0.82

Virtus Family Office LLC Buys New Shares in Gilead Sciences, Inc. $GILD

Gilead Sciences Raises 2026 Sales Forecast Amid Acquisition Costs, ETPharma

Gilead Sciences (GILD) Announces Quarterly Dividend and Adjusts 2026 Outlook

Gilead Sciences, Inc. $GILD Shares Sold by Patton Albertson Miller Group LLC - Zolmax

Gilead Sciences, Inc. (NASDAQ:GILD) to Issue Quarterly Dividend of $0.82 - Stock Observer

Gilead Sciences (GILD) Stock Drops Despite Q1 Beat on Massive Acquisition Charges

Gilead Sciences, Inc. $GILD Holdings Decreased by GRIMES & Co WEALTH MANAGEMENT LLC

Gilead Sciences (GILD) Reports Strong Q1 2026 Earnings and Raises Sales Guidance

Gilead Sciences, Inc. $GILD Shares Sold by Patton Albertson Miller Group LLC - Daily Political

Gilead Sciences Q1 Earnings Call Highlights

Gilead Sciences (NASDAQ:GILD) Issues Quarterly Earnings Results

Diagnosing and defining MASLD in people living with chronic hepatitis B

Gilead Sciences Inc. Reports Advance In Q1 Income

Gilead Sciences (NASDAQ:GILD) Issues FY 2026 Earnings Guidance

Gilead Sciences (NASDAQ:GILD) Releases FY 2026 Earnings Guidance - Daily Political

Gilead Sciences shares decline 1.36% ahead of first quarter earnings

A Look At Gilead Sciences (GILD) Valuation After FDA Priority Review For New HIV Tablet

WealthShield Partners LLC Makes New $1.73 Million Investment in Gilead Sciences, Inc. $GILD - Stock Observer

Indivisible Partners Purchases New Stake in Gilead Sciences, Inc. $GILD

Gilead Sciences News | Markets Insider

Galapagos rapporteert financiële resultaten over het eerste kwartaal van 2026 en geeft bedrijfsupdate

Gilead Case Could Reshape Drug Liability: California Brief

Swedbank AB Grows Stock Position in Gilead Sciences, Inc. $GILD - Zolmax

Gilead Sciences, Inc. $GILD Shares Sold by Sprucegrove Investment Management Ltd.

Equitable Trust Co. Has $6.07 Million Holdings in Gilead Sciences, Inc. $GILD

Mitsubishi UFJ Asset Management Co. Ltd. Has $330.64 Million Position in Gilead Sciences, Inc. $GILD - Stock Observer

GILEAD SCIENCES, INC. Reduces Stake in Arcellx Inc by 6,720,703 Shares

RNC Capital Management LLC Increases Stake in Gilead Sciences, Inc. $GILD

Morse Asset Management Inc Invests $1.22 Million in Gilead Sciences, Inc. $GILD

Use of Gilead's HIV prevention shot rises, but US insurance gaps remain - Yahoo News Canada

Gilead Sciences, Inc. $GILD Shares Acquired by M&T Bank Corp

Gilead Sciences, Inc. $GILD Shares Purchased by QRG Capital Management Inc. - Stock Observer

Alliance Wealth Advisors LLC UT Cuts Stake in Gilead Sciences, Inc. $GILD

Earnings Strength Moves Into Focus as the Busiest Week of Q1 Season Begins | Investing.com UK

Earnings Strength Moves Into Focus as the Busiest Week of Q1 Season Begins | Investing.com Canada

Gilead Sciences, Inc. $GILD Shares Bought by Triasima Portfolio Management inc.

Can You Sue A Drug Company For Not Inventing Faster?

Gilead Sciences, Inc. $GILD Shares Sold by Varma Mutual Pension Insurance Co - Stock Observer

Pinnacle Wealth Management Advisory Group LLC Cuts Stock Position in Gilead Sciences, Inc. $GILD - Stock Observer

Is Trial Failures And Gilead Pullback Altering The Investment Case For Arcus Biosciences (RCUS)?

Hussman Strategic Advisors Inc. Cuts Stake in Gilead Sciences, Inc. $GILD - Daily Political

Strs Ohio Reduces Stock Holdings in Gilead Sciences, Inc. $GILD

Gilead Sciences, Inc. $GILD Stock Holdings Increased by Sigma Planning Corp

Assessing Gilead Sciences (GILD) Valuation As Long Term Returns Contrast With Recent Share Performance

GILD: Future Returns Will Hinge On Executing Oncology And ADC Acquisitions

Biopharma M&A Surge Expected in 2026 Amid Patent Expirations

Big Pharma M&A set for mega year as patent expiries drive deal urgency

Jennison Associates LLC Buys 741,044 Shares of Gilead Sciences, Inc. $GILD - Zolmax

Oppenheimer & Co. Inc. Cuts Position in Gilead Sciences, Inc. $GILD

Gilead Sciences, Inc. $GILD Shares Sold by New York State Teachers Retirement System

US Bancorp DE Has $105.44 Million Stock Position in Gilead Sciences, Inc. $GILD

Fifth Third Bancorp Increases Position in Gilead Sciences, Inc. $GILD

Danske Bank A S Sells 45,529 Shares of Gilead Sciences, Inc. $GILD

Keybank National Association OH Has $14.15 Million Stock Position in Gilead Sciences, Inc. $GILD - Zolmax

Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O'day Sells 10,000 Shares - Zolmax

Is Gilead Sciences, Inc. (GILD) A Good Stock To Buy Now?

Gilead Sciences Annual Meeting: Directors, Pay Win Big; Pipeline Launches and Acquisitions Highlighted - Stock Observer

Gilead Sciences, Inc. $GILD Shares Sold by Verity Asset Management Inc.

Gilead Sciences, Inc. $GILD Position Trimmed by State of New Jersey Common Pension Fund D

FY2026 EPS Estimates for Gilead Sciences Reduced by Analyst

Is It Time To Revisit Gilead Sciences (GILD) After Recent Share Price Pullback

Gilead Sciences (NASDAQ:GILD) CEO Sells $1,291,600.00 in Stock

GILD: Gilead's New HIV Treatment Gains FDA Acceptance

How Investors May Respond To Kymera Therapeutics (KYMR) FDA Fast Track Win And Gilead Trial Expansion

Morgan Stanley Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Rating of "Moderate Buy" by Analysts

Gilead Sciences (GILD) Closes $7.8B Arcellx Buyout - What Investors Need to Know

Gilead Sciences Completes Acquisition of Arcellx (ACLX)

Merck Broadens Growth Story With Heart Campaign And New Drug Approvals

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel | Morningstar

Mitsubishi UFJ Trust & Banking Corp Decreases Stake in Gilead Sciences, Inc. $GILD

Gilead Sciences reports new GTPase KRAS G12D inhibitors and degraders | BioWorld

M&T Bank Corp Sells 147,548 Shares of Gilead Sciences, Inc. $GILD - Daily Political

Gilead Sciences (GILD) Set to Acquire Arcellx

Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial

Gilead Sciences Inc. (GILD): Growing Popularity as Defensive Stock

Top Pharmaceutical Stocks To Keep An Eye On - April 26th - Daily Political

US Economy on Stagflation Watch: Apollo Global Management's Outlook

AI Podcast: Fresh Insights on Fed Rate Cut Timing - News in a New Way

The Week Ahead: ISM services, SMCI

Week ahead: Wall Street’s Magnificent Seven earnings are up

Week ahead: Earnings season climax

Week ahead: RBA poised to hike?

Week ahead: Megacap tech and 1-in-3 Dow components set to report

Trump's Sudden Russia Policy Shift: Rubio's Influence and Implications

Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty

September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations

Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge

Fund Managers Cautious in Q4: AI, Inflation, and Monetary Policy in Focus

US Government Shutdown Threatens October Inflation Data Release

US-EU Relations: Russia Sanctions Unite Despite Trade Tensions

BOJ Warns of Japan Stock Market Overheating, U.S. Trade Policy Risk